NYBA
New York Biotechnology Association
 
 
More...
NYBA: Archived News
NYBA News | Member News | Press Release
 
News type
OSI Pharmaceuticals Inc.
Headline: U.S. Patent And Trademark Office Grants Reissued Patent Replacing OSI Pharmaceuticals'
Tarceva(R) Composition Of Matter Patent
Date: 29-Dec-2009
News Type: Member News
OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) today announced that the U.S. Patent & Trademark Office (PTO) has granted reissue patent RE41,065, replacing Tarceva's(R) (erlotinib) composition of matter patent (formerly No.5,747,498). The Company had applied for the reissue patent in February 2008, and on September 17, 2009 the Company had announced that the PTO had issued a "Notice of Allow...
Details »
 
Pfizer Inc.
Headline: Pfizer’s Lyrica Receives Complete Response Letter From FDA For Generalized Anxiety
Disorder Monotherapy Treatment
Date: 23-Dec-2009
News Type: Member News
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the Food and Drug Administration (FDA) issued a Complete Response letter regarding the company’s New Drug Application (NDA) for Lyrica® (pregabalin) capsules CV as a monotherapy treatment for generalized anxiety disorder (GAD). The FDA determined that the data contained in the NDA were insufficient to support appr...
Details »
 
Bristol-Myers Squibb Company
Headline: Bristol-Myers Squibb And Mead Johnson Announce Final Results Of The Exchange Offer
Date: 23-Dec-2009
News Type: Member News
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Mead Johnson Nutrition Company (NYSE: MJN) announced today the final results of the offer by Bristol-Myers Squibb to exchange up to 170,000,000 shares of common stock of Mead Johnson for outstanding shares of Bristol-Myers Squibb common stock that were validly tendered and not validly withdrawn. The offer ex...
Details »
 
Amgen, Inc.
Headline: Amgen Resolves EPO Patent Dispute With Roche
Date: 22-Dec-2009
News Type: Member News
Roche Admits Infringement And Validity Of Amgen's EPO Patents; Court Enters Permanent Injunction; Amgen Allows Roche's MIRCERA Onto U.S. Market In Mid-2014 THOUSAND OAKS, Calif., Dec 22, 2009 /PRNewswire-FirstCall via COMTEX/ -- Amgen (Nasdaq: AMGN) announced today that the United States (U.S.) District Court in Boston has entered final judgment and a permanent injunction agains...
Details »
 
OSI Pharmaceuticals Inc.
Headline: OSI Pharmaceuticals Updates Preliminary Revenue & Re-affirms Adjusted Earnings Growth
Rate Guidance For 2010
Date: 22-Dec-2009
News Type: Member News
Mid-teen revenue growth for 2010 Adjusted earnings per share growth of 10% or more for 2010 OSI repurchased $79.5 million of 2023 & 2038 convertible bonds during December 2009 MELVILLE, N.Y., Dec 22, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) today provided an update to the preliminary revenue and adjusted earnings per share growth...
Details »
 
Amgen, Inc.
Headline: Amgen's Roger M. Perlmutter, M.D., Ph.D., Named 2009 AAAS Fellow, Recognized For
Discovery, Development Of Novel Medicines
Date: 18-Dec-2009
News Type: Member News
Amgen (Nasdaq: AMGN) announced today that Roger M. Perlmutter, M.D., Ph. D., Amgen's executive vice president of Research & Development, has been elected a 2009 Fellow of the American Association for the Advancement of Science (AAAS). Each year the AAAS Council elects members whose "efforts on behalf of the advancement of science or its applications are scientifically or socially disti...
Details »
 
Amgen, Inc.
Headline: Amgen Receives CHMP Positive Opinion For Prolia(TM) (Denosumab) In The European Union
Date: 18-Dec-2009
News Type: Member News
Amgen Inc. (Nasdaq: AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has announced a positive opinion for the marketing authorization of Prolia((TM)) (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in...
Details »
 
Pfizer Inc.
Headline: FDA Approves SPIRIVA® HandiHaler® For The Reduction Of COPD Exacerbations
Date: 17-Dec-2009
News Type: Member News
First Once-Daily Steroid-Free Maintenance Treatment That Has Been Shown to Reduce Exacerbations for People with COPD RIDGEFIELD, Conn. & NEW YORK--(BUSINESS WIRE)--Boehringer Ingelheim Pharmaceuticals, Inc. and Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved SPIRIVA® HandiHaler® (tiotropium bromide inhalation powder)...
Details »
 
Bristol-Myers Squibb Company
Headline: Bristol-Myers Squibb Sets Exchange Ratio Of 0.6313 For The Exchange Offer
Date: 16-Dec-2009
News Type: Member News
-Bristol-Myers Squibb Company (NYSE: BMY) and Mead Johnson Nutrition Company (NYSE: MJN) announced today that Bristol-Myers Squibb has set the exchange ratio for its offer to exchange up to 170.0 million shares of common stock of Mead Johnson for outstanding shares of Bristol-Myers Squibb common stock that are validly tendered and not validly withdrawn. The exchange ratio is 0.6313 shares...
Details »
 
Genentech Inc.
Headline: FDA Advisory Committee Recommends Against Approving Tarceva For First-Line Maintenance Use
In Advanced Non-Small Cell Lung Cancer
Date: 16-Dec-2009
News Type: Member News
OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 12 to one recommending against approval of the daily pill Tarceva® (erlotinib) for first-line maintenance use in people with advanced or metastatic...
Details »
 
« Previous Next »
   
  © 2008 New York Biotechnology Association HOME | ABOUT NYBA | CONTACT US | SITE MAP Website by Axxiem